BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24574829)

  • 1. Risks associated with sunitinib use and monitoring to improve patient outcomes.
    Choi BS
    Korean J Intern Med; 2014 Jan; 29(1):23-6. PubMed ID: 24574829
    [No Abstract]   [Full Text] [Related]  

  • 2. Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea.
    Baek SH; Kim H; Lee J; Kim DK; Oh KH; Kim YS; Han JS; Kim TM; Lee SH; Joo KW
    Korean J Intern Med; 2014 Jan; 29(1):40-8. PubMed ID: 24574832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib-induced thrombotic microangiopathy.
    Noronha V; Punatar S; Joshi A; Desphande RV; Prabhash K
    J Cancer Res Ther; 2016; 12(1):6-11. PubMed ID: 27072203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
    Patel TV; Morgan JA; Demetri GD; George S; Maki RG; Quigley M; Humphreys BD
    J Natl Cancer Inst; 2008 Feb; 100(4):282-4. PubMed ID: 18270341
    [No Abstract]   [Full Text] [Related]  

  • 5. Allergic interstitial nephritis possibly related to sunitinib use.
    Khurana A
    Am J Geriatr Pharmacother; 2007 Dec; 5(4):341-4. PubMed ID: 18179992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of sunitinib in hemodialysis.
    Izzedine H; Etienne-Grimaldi MC; Renée N; Vignot S; Milano G
    Ann Oncol; 2009 Jan; 20(1):190-2. PubMed ID: 18801884
    [No Abstract]   [Full Text] [Related]  

  • 7. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.
    Kalantari HR
    Br J Cancer; 2009 Oct; 101(7):1222-3; author reply 1224. PubMed ID: 19755985
    [No Abstract]   [Full Text] [Related]  

  • 8. "Pseudocavitation" in thymic carcinoma during treatment with sunitinib.
    Tiseo M; Rajan A; Thomas A; Giaccone G
    J Thorac Oncol; 2013 Apr; 8(4):511-2. PubMed ID: 23486269
    [No Abstract]   [Full Text] [Related]  

  • 9. Sunitinib-induced thyrotoxicosis.
    Piñar D; Boix E; Meana JA; Herrero J
    J Endocrinol Invest; 2009 Dec; 32(11):941-2. PubMed ID: 19636224
    [No Abstract]   [Full Text] [Related]  

  • 10. Erosive nappy erythema following sunitinib intake.
    Kharmoum S; Errihani H
    Pan Afr Med J; 2013; 14():46. PubMed ID: 23560129
    [No Abstract]   [Full Text] [Related]  

  • 11. Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma.
    Flaig TW; Kim FJ; La Rosa FG; Breaker K; Schoen J; Russ PD
    Invest New Drugs; 2009 Feb; 27(1):83-7. PubMed ID: 18563296
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.
    Kim KH; Kim HY; Kim HR; Sun JM; Lim HY; Lee HJ; Lee S; Bae WK; Rha SY; ;
    Eur J Cancer; 2014 Mar; 50(4):746-52. PubMed ID: 24332573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction.
    Takahashi D; Nagahama K; Tsuura Y; Tanaka H; Tamura T
    Clin Exp Nephrol; 2012 Apr; 16(2):310-5. PubMed ID: 21964704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelosuppression by sunitinib is flt-3 genotype dependent.
    van Erp NP; Mathijssen RH; van der Veldt AA; Haanen JB; Reyners AK; Eechoute K; Boven E; Wessels JA; Guchelaar HJ; Gelderblom H
    Br J Cancer; 2010 Aug; 103(5):757-8. PubMed ID: 20683446
    [No Abstract]   [Full Text] [Related]  

  • 15. Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy.
    van der Veldt AA; van den Eertwegh AJ; Hoekman K; Barkhof F; Boven E
    Ann Oncol; 2007 Oct; 18(10):1747-50. PubMed ID: 17890217
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of hemodialyzed patient with sunitinib.
    Reckova M; Kakalejcik M; Beniak J
    Ann Oncol; 2009 Feb; 20(2):392-3. PubMed ID: 19136449
    [No Abstract]   [Full Text] [Related]  

  • 17. Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.
    Vickers MM; Heng DY; Hemmelgarn B; Eigl BJ
    Clin Genitourin Cancer; 2009 Oct; 7(3):E104-6. PubMed ID: 19815480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurosensory retinal detachment due to sunitinib treatment.
    Wegner A; Khoramnia R
    Eye (Lond); 2011 Nov; 25(11):1517-8. PubMed ID: 21852804
    [No Abstract]   [Full Text] [Related]  

  • 19. Sporadic CNS hemangioblastomatosis, response to sunitinib and secondary polycythemia.
    Reyes-Botero G; Gállego Pérez-Larraya J; Sanson M
    J Neurooncol; 2012 Apr; 107(2):439-40. PubMed ID: 22076450
    [No Abstract]   [Full Text] [Related]  

  • 20. Exfoliative esophagitis in a patient with metastatic renal cell carcinoma during sunitinib treatment.
    Huang J; Wang T; Huang Y
    Med Oncol; 2013 Mar; 30(1):436. PubMed ID: 23283650
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.